Investments - Additional Information (Details) - USD ($)			1 Months Ended	3 Months Ended					9 Months Ended		12 Months Ended
	Dec. 01, 2021	Jan. 28, 2021	Jun. 30, 2021	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 28, 2022	Sep. 09, 2022	Jul. 29, 2022	Jul. 28, 2022	Jun. 30, 2022	Feb. 01, 2022
Stock issued for warrants exercised, shares			5,956,544
Debt instrument amount funded for transaction									$ 1,666,667
Part of transaction purchased, amount									3,333,333
Stock issued for warrants exercised			$ 8,500,000					$ 9,544,623
Short-term investments - debt securities (Note 7)				$ 2,619,292		$ 2,000,000			2,619,292		$ 2,000,000
Unrealized loss on convertible debt security							$ 2,588,916			$ 87,316
Marketable securities shares sold						477,405				587,530
Realized gain on convertible debt securities									$ 287,778
Common stock, par value				$ 0.001		$ 0.001			$ 0.001		$ 0.001
Shares classified as marketable securities										5,960,829
Realized gain (loss) on securities							(173,282)		$ (349,920)	$ (13,951,752)
Gain recognized on loan transaction										5,700,000
Amount of loans receivables acquired										18,200,000
Cost associated with acquisition of receivables loan										15,500,000
Proceeds from sale of own shares										32,600,000
Provision for investor										11,300,000
Note payable - short-term (Note 3)						$ 114,688					$ 114,688
Exercise of warrants										9,544,623
Common stock, shares issued				13,091,883		13,017,943			13,091,883		13,017,943
Class B Shares And Warrants [Member]
Unrealized loss on convertible debt security				$ (194,000)			(123,000)		$ 11,000,000.0	1,000,000.0
Stock Warrants [Member]
Exercise of warrants										9,500,000
IPO [Member]
Percentage of sponsors initial risk		69.50%
Proceeds from issuance initial public offering		$ 103,500,000
Gain or loss on equity investment in unconsolidated subsidiary									12,700,000	4,600,000
IPO [Member] | Stock Warrants [Member]
Private warrants hold by sponsors		5,738,000
LMFA Sponsor LLC [Member]
Unrealized loss on convertible debt security				$ (194,000)			(184,000)		$ (1,651,000)	(3,626,000)
Purchased aggregate of private placement warrants									5,738,000
Investment warrants exercise price									$ 1.00
Class A Common Stock [Member] | LMFA Sponsor LLC [Member]
Investment warrants exercise price									$ 11.50
Class A And Class B Common Shares [Member] | IPO [Member]
Percentage of common stock hold by sponsors		20.00%
BORQS Technologies [Member]
Marketable securities shares sold				0					8,759,094
Proceeds from sale marketable securities									$ 2,300,000
Realized net gain (loss) related to sale of securities									$ (350,000)
Symbiont IO [Member]
Stock issued for warrants exercised, shares											700,000
Common stock, par value						$ 3.0642					$ 3.0642
Investment expiry date											Dec. 01, 2026
Exercise of warrants											$ 2,000,000
Symbiont IO [Member] | ROFR Agreement {Member]
Debt Instrument, Interest Rate, Stated Percentage				16.00%					16.00%
Accrued interest income				$ 267,000		$ 27,000			$ 267,000		$ 27,000
Common stock, par value				$ 3.0642					$ 3.0642
Drawn amount	$ 2,000,000
Investment maturity date				Dec. 01, 2021					Dec. 01, 2021
Investment expiry date									Dec. 01, 2022
LMF Acquisition Opportunities Inc [Member] | Class B Shares And Warrants [Member]
Common stock, par value				$ 0.0001					$ 0.0001
Investments in affiliates shares				5,738,000					5,738,000
Warrant Exercise Price				$ 11.50					$ 11.50
Percentage of ownership in subsidiary									70.00%
Value of shares under acquisition				$ 25,000					$ 25,000
LMF Acquisition Opportunities Inc [Member] | Private Placement Warrants [Member] | Stock Warrants [Member]
Warrant Exercise Price		$ 1.00
Proceeds from issuance of private placement		$ 5,738,000
LMF Acquisition Opportunities Inc [Member] | Class A Common Stock [Member]
Common stock, par value														$ 0.10
LMF Acquisition Opportunities Inc [Member] | Class A Common Stock [Member] | IPO [Member]
Common stock, par value		$ 10.00
Common stock, shares issued		10,350,000
Gross proceeds from common stock issuance		$ 103,500,000
Maximum [Member] | Symbiont IO [Member] | ROFR Agreement {Member]
Note payable - short-term (Note 3)	$ 3,000,000
Subsequent Event [Member]
Debt instrument principal amount												$ 700,000
Debt Instrument, Interest Rate, Stated Percentage												7.00%
Convertible Debt Securities [Member]
Convertible note									844,882	4,231,760
Accrued interest income				$ 17,753			$ 160,954		17,753	$ 160,954
Realized gain on convertible debt securities									287,778
Short-term Investments [Member]
Sale of stock, price per share							$ 0.592			$ 0.592
Unrealized loss on convertible debt security							$ 87,316			$ 87,316
Converted common stock							1,422,091
Convertible notes, conversion price							$ 0.6534			$ 0.6534
Short-term Investments [Member] | Convertible Debt Securities [Member]
Short-term investments - debt securities (Note 7)							$ 841,878			$ 841,878
Convertible note							4,100,000
Accrued interest income							$ 131,760			$ 131,760
Converted common stock											3,863,200
Marketable securities shares sold					4,895,894
Realized gain on convertible debt securities									(395,000)
Remaining Convertible debt with Accrued Interest income									$ 965,096
Common stock, par value				$ 0.25					$ 0.25
Realized gain (loss) on securities									$ 45,000
Short-term Investments [Member] | Convertible Debt Securities [Member] | Borqs Convertible Note Plus Accrued Interest
Converted common stock							5,960,829
Short-term Investments [Member] | Convertible Debt Securities [Member] | Remaining Borqs Convertible Note Plus Accrued Interest
Converted common stock									3,863,200
Realized gain on convertible debt securities									$ 287,778
Seastar Medical [Member] | Credit Agreement [Member]
Percentage of interest rate on advances				15.00%					15.00%
Accrued interest income				$ 3,000					$ 3,000
Amount loaned under credit agreement				$ 350,000					$ 350,000
Investment maturity date				Oct. 25, 2022					Oct. 25, 2022
Seastar Medical [Member] | Maximum [Member] | Credit Agreement [Member]
Agreed amount of advances													$ 700,000
LMF Acquisition Opportunities Inc [Member]
Debt instrument principal amount				$ 5,000,000					$ 5,000,000
Senior notes				$ 20,000,000					$ 20,000,000
Debt instrument maturity month and year									2023-02
Debt Instrument, Interest Rate, Stated Percentage				8.00%					8.00%
Debt instrument discount rate percentage									10.00%
Debt instrument warrant coverage rate									90.00%
Debt instrument convertible conversion price rate									110.00%
Stock issued for warrants exercised, shares									2,922,078
Unsecured Promissory Note [Member]
Debt instrument principal amount															$ 1,750,000		$ 500,000
Drawn amount									$ 1,750,000
Unsecured Promissory Note [Member] | LMF Acquisition Opportunities Inc [Member]
Principal amount of notes receivable														$ 1,035,000
Aggregate amount deposited in trust account														$ 1,035,000
Original Sponsor Notes [Member] | LMF Acquisition Opportunities Inc [Member]
Principal amount of notes receivable																$ 1,750,000
Sponsor Notes [Member] | Subsequent Event [Member] | LMF Acquisition Opportunities Inc [Member]
Principal amount of notes receivable												$ 2,785,000